论文部分内容阅读
目的:观察依达拉奉治疗急性脑出血的临床疗效和安全性。方法:选择符合条件的持续住院14d以上的脑出血患者60例,随机分为治疗组和对照组,各30例。两组均根据出血量给予不同剂量的脱水药物和脑细胞活化药,并控制血压和血糖。治疗组在此基础上,给予依达拉奉30mg加入0.9%氯化钠注射液100ml,ivd,bid,共14d。治疗后第14天对两组患者进行神经功能缺损评分及疗效评定。结果:治疗14d后,治疗组神经功能缺损评分由治疗前的(20.19±10.4)分下降到治疗后的(12.89±7.24)分(P<0.05),对照组神经功能缺损评分由治疗前的(20.65±9.95)分下降到治疗后的(16.18±7.17)分,但差异无统计学意义(P>0.05);两组治疗后比较差异有统计学意义(P<0.05)。治疗组无明显不良反应。结论:依达拉奉治疗急性脑出血安全有效。
Objective: To observe the clinical efficacy and safety of edaravone in the treatment of acute cerebral hemorrhage. Methods: Sixty consecutive patients with cerebral hemorrhage who were hospitalized for more than 14 days were selected and randomly divided into treatment group and control group, with 30 cases in each group. Both groups were given different doses of dehydration drugs and brain cell activating drugs according to the amount of bleeding, and controlled blood pressure and blood sugar. On the basis of the treatment group, edaravone 30mg was added to 0.9% sodium chloride injection 100ml, ivd, bid for 14 days. On the fourteenth day after treatment, the neurological deficit scores and the curative effects were evaluated. Results: After 14 days of treatment, the score of neurological deficit in the treatment group decreased from (20.19 ± 10.4) before treatment to (12.89 ± 7.24) minutes after treatment (P0.05) 20.65 ± 9.95) to 16.18 ± 7.17 after treatment, but the difference was not statistically significant (P> 0.05). There was significant difference between the two groups after treatment (P <0.05). Treatment group no obvious adverse reactions. Conclusion: Edaravone is safe and effective in treating acute cerebral hemorrhage.